荣昌生物(688331/09995)5月29日宣布完成1900万股新H股配售,每股定价42.44港元,募资净额约7.96亿港元。这是公司自2021年以来的第四次港股再融资,配售股份占现有H股的10.02%,所筹资金的90%将投入核心产品泰它西普的适应症拓展,10%用于日常运营。对深陷资金困局的荣昌生物而言,这7.96亿港元无异于一场及时雨——按一季度超6亿元的运营开支估算,这笔钱仅够支撑三个月的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.